Marker Therapeutics Stock Drops After Report About Lymphoma Treatment
1. Marker Therapeutics updated on Phase 1 APOLLO study for MT-601. 2. MT-601 demonstrated a 66% response rate in Non-Hodgkin Lymphoma patients. 3. No dose-limiting toxicities were reported, indicating robust safety. 4. Future updates on clinical data are expected in the first half of 2026. 5. MRKR stock is currently down 14.28%, trading at $1.08.